Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 2013, 725410

Tyrosine Kinase Inhibitors Induced Thyroid Dysfunction: A Review of Its Incidence, Pathophysiology, Clinical Relevance, and Treatment

Affiliations
Review

Tyrosine Kinase Inhibitors Induced Thyroid Dysfunction: A Review of Its Incidence, Pathophysiology, Clinical Relevance, and Treatment

Hala Ahmadieh et al. Biomed Res Int.

Abstract

Tyrosine kinase inhibitors (TKI) belong to a new class of molecular multitargeted anticancer therapy which targets different growth factor receptors and hence attenuates cancer cell survival and growth. Since their introduction as adjunct treatment for renal cell carcinoma and gastrointestinal stromal tumors (GIST), a number of reports have demonstrated that TKI can induce thyroid dysfunction which was especially more common with sunitinib maleate. Many mechanisms with respect to this adverse effect of tyrosine kinase inhibitors have been proposed including their induction of thyroiditis, capillary regression in the thyroid gland, antithyroid peroxidase antibody production, and their ability to decrease iodine uptake by the thyroid gland. Of interest is the observation that TKI-induced thyroid dysfunction may actually be protective as it was shown to improve overall survival, and it was suggested that it may have a prognostic value. Followup on thyroid function tests while patients are maintained on tyrosine kinase inhibitor is strongly recommended. When thyroid dysfunction occurs, appropriate treatment should be individualized depending on patients symptoms and thyroid stimulating hormone level.

Similar articles

See all similar articles

Cited by 10 articles

See all "Cited by" articles

References

    1. Le Tourneau C, Faivre S, Raymond E. New developments in multitargeted therapy for patients with solid tumours. Cancer Treatment Reviews. 2008;34(1):37–48. - PubMed
    1. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. The Journal of Pharmacology and Experimental Therapeutics. 2005;315(3):971–979. - PubMed
    1. Cilloni D, Messa E, Messa F, et al. Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes. Annals of the New York Academy of Sciences. 2006;1089:411–423. - PubMed
    1. Paul M, Mukhopadhyay A. Tyrosine kinase—role and significance in cancer. International Journal of Medical Sciences. 2004;1(2):101–115. - PMC - PubMed
    1. Izzedine H, Buhaescu I, Rixe O, Deray G. Sunitinib malate. Cancer Chemotherapy and Pharmacology. 2007;60(3):357–364. - PubMed

MeSH terms

Substances

LinkOut - more resources

Feedback